Novo Nordisk Brings Renewed Education Efforts, But Not New Products, To Japan In 2012
This article was originally published in PharmAsia News
Novo Nordisk pushes the benefits of early diabetes treatment to spur Victoza and insulin growth.
You may also be interested in...
Market-leader Novo is confident it can continue to innovate in insulin – and command premium prices
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.